Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

 
REVIEW ARTICLE
Ahead of print publication  

Epigenetic therapies in patients with solid tumors: Focus on monotherapy with deoxyribonucleic acid methyltransferase inhibitors and histone deacetylase inhibitors


1 Department of Family Practice, Medical University of Silesia (SUM), Katowice-Zabrze, Zabrze, Poland
2 Department of Pharmacy, Medical University of Silesia (SUM), Katowice, Poland

Correspondence Address:
Rygiel Katarzyna,
Department of Family Practice, Medical University of Silesia (SUM), Katowice-Zabrze, Poland; 3 Maja St.13/15, 41-800 Zabrze
Poland
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jcrt.JCRT_403_17

 > Abstract 


Epigenomics is the study of the gene expression changes due to epigenetic processes and not due to the deoxyribonucleic acid (DNA) base sequence alterations. The key mechanisms of epigenetic regulation include DNA methylation, histone modifications, and noncoding RNAs. Epigenetic alterations in cancer are predominantly linked with hypermethylation of promoters of the tumor suppressor genes, global DNA hypomethylation, and increased expression of histone deacetylases (HDAC). There is a growing need to investigate epigenetic patterns and to provide safe and effective, innovative therapeutic strategies for oncology patients, who did not improve on traditional anticancer regimens. The epi-drugs (e.g., DNA methyltransferase inhibitors, e.g., azacitidine and decitabine and HDAC inhibitors, e.g., vorinostat and romidepsin) have been approved for the clinical use. In this paper, we provide a brief overview of the mechanisms of action and targets for novel epi-drugs, focusing on their potential clinical applications in patients with solid tumors, resistant to standard oncology treatments.

Keywords: Azacitidine, deoxyribonucleic acid methyltransferase inhibitors, epigenetic clinical studies, histone deacetylase inhibitors, solid tumors, vorinostat



How to cite this URL:
Katarzyna R, Lucyna B. Epigenetic therapies in patients with solid tumors: Focus on monotherapy with deoxyribonucleic acid methyltransferase inhibitors and histone deacetylase inhibitors. J Can Res Ther [Epub ahead of print] [cited 2019 Jan 20]. Available from: http://www.cancerjournal.net/preprintarticle.asp?id=244213

.






 

 
Top
 
 
  Search
 
     Search Pubmed for
 
    -  Katarzyna R
    -  Lucyna B
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  >Abstract
  In this article

 Article Access Statistics
    Viewed136    
    PDF Downloaded2    

Recommend this journal